You are viewing the site in preview mode
Skip to main content
|
Characteristics
|
All cohort (n = 146)
|
|---|
|
Age, y, median. (IQR)
|
60 (54–66.25)
|
|
Sex, no. (%)
| |
|
Male
|
113 (77.4)
|
|
Female
|
33 (22.6)
|
|
BMI, kg/m2, median. (IQR)
|
23.87 (21.44–26.65)
|
|
Symptom at presentation, no. (%)
| |
|
Absent
|
38 (26)
|
|
Present
|
108 (74)
|
|
ASA score, no. (%)
| |
|
I–II
|
129 (88.3)
|
|
III
|
17 (11.7)
|
|
Surgical approach, no. (%)
| |
|
Open
|
59 (40.4)
|
|
Laparoscopic
|
87 (59.6)
|
|
Surgical time, min, median. (IQR)
|
305.5 (224.25–400)
|
|
Blood loss, ml, median. (IQR)
|
600 (200–1650)
|
|
Transfusion, no. (%)
|
61 (41.8)
|
|
Segmental resection of vena cava, no. (%)
|
27 (18.5)
|
|
Tumour side, no. (%)
| |
|
Left
|
52 (35.6)
|
|
Right
|
94 (64.4)
|
|
Tumour size, cm, median. (IQR)
|
8.25 (6.48–10)
|
|
Tumour thrombus level, no. (%)
| |
|
0–II
|
118 (80.8)
|
|
III–IV
|
28 (19.2)
|
|
Invasion of venous wall, no. (%)
|
53 (41.4)
|
|
Histology subtype, no. (%)
| |
|
Clear cell
|
124 (84.9)
|
|
Non-CCRCC
|
22 (15.1)
|
|
Nuclear grade, no. (%)
| |
|
I–II
|
61 (41.7)
|
|
III–IV
|
85 (58.3)
|
|
lymph node metastasis, no. (%)
|
9 (5.9)
|
|
Necrosis, no. (%)
|
66 (45.8)
|
|
SSIGN score
| |
|
Low-risk (score 2–4)
|
49 (33.5)
|
|
Intermediate-risk (score 5–7)
|
76 (52.1)
|
|
High-risk (score 8–11)
|
21 (13.4)
|
- IQR interquartile range, BMI body mass index, ASA American Society of Anesthesiologists, CCRCC clear cell renal cell carcinoma
